On October 29, 2006 the Food and Drug Administration issued a warning that aprotinin may have serious kidney and cardiovascular toxicity. The producer, Bayer, reported to the FDA that additional observation studies showed that it may increase the chance for death, serious kidney damage, congestive heart failure and strokes.
On October 29, 2006, the Food and Drug Administration issued a warning about aprotinin's potential for serious kidney and cardiovascular harm. The manufacturer, Bayer, reported to the FDA that additional studies showed an increased risk of death, severe kidney damage, congestive heart failure, and strokes.